OKYO - OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment March, 31 2025 10:01 AM OKYO Pharma Limited 2025-03-31 10:01:55 ET More on OKYO Pharma OKYO Pharma receives $1.4 million in non-dilutive funding, stock up Seeking Alpha’s Quant Rating on OKYO Pharma Historical earnings data for OKYO Pharma Financial information for OKYO Pharma For further details see: OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment